Dr. Steven Quay, President and CEO, highlighted the progress made in the (Z)-endoxifen development strategy over the past year, noting the FDA's grant of Rare Pediatric Disease and Orphan Drug designations for the treatment of Duchenne Muscular Dystrophy (DMD). These designations are expected to expedite the review process and provide potential financial benefits. The company is also focusing on aligning resources for potential commercialization while expanding its clinical leadership team with experienced professionals.
Atossa's financial results reflect a net loss of $34.8 million for the year, compared to a net loss of $25.5 million in 2024. The increase in net loss was driven by higher operating expenses, particularly in research and development, which totaled $21.2 million for 2025. The company is optimistic about its strategic direction and the potential for (Z)-endoxifen to address significant unmet medical needs in both oncology and rare diseases.
The company’s balance sheet remains strong, with cash and cash equivalents of approximately $41.3 million as of December 31, 2025. Atossa is committed to advancing its clinical programs and achieving key milestones in the coming year, as it continues to explore opportunities in the breast cancer space and other serious health conditions. The company’s innovative approach and recent recognitions, including the Clinical Trials Arena Research and Development Excellence Award, position it well for future growth.
